Skip to content

Arcutis Biotherapeutics

US · ARQT #2465 by market cap Listed 2020
26.36 -0.81 -2.98%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/7/1
  • Rating change
    Cantor Fitzgerald Initiates Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $48
    Market Newswire · 2026/10/15
  • Rating change
    Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Cuts Target Price to $35
    Market Newswire · 2026/2/28
  • Morgan Stanley Initiates Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $38
    Market Newswire · 2026/11/5
  • Rating change
    Goldman Sachs Maintains Arcutis Biotherapeutics(ARQT.US) With Hold Rating, Raises Target Price to $33
    Market Newswire · 2026/2/27
  • Rating change
    Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/7/15
  • H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/11/5
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)
    TipRanks · 2026/5/26
  • Rating change
    A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36
    Market Newswire · 2026/5/8
  • Rating change
    H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/8/11
  • Rating change
    Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/5/26
  • Rating change
    A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $40
    Market Newswire · 2026/8/7
  • Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q3 Revenue $143.9M, Vs. FactSet Est of $142.6M
    MT Newswires · 2026/11/5
  • Rating change
    Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/4/22
  • TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/11/5
  • Rating change
    Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $35
    Market Newswire · 2026/2/27
  • Guggenheim Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $44
    Market Newswire · 2026/10/19
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)
    TipRanks · 2026/8/11
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN)
    TipRanks · 2026/4/22
  • Rating change
    TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/4/23
  • Rating change
    A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37
    Market Newswire · 2026/2/27
  • Rating change
    TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/1/29
  • Form 144 | Arcutis Biotherapeutics(ARQT.US) Insider Proposes to Sell 8.55 Million in Common Stocks
    Market Newswire · 2026/9/17
  • Rating change
    H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/2/3
  • Rating change
    Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $37
    Market Newswire · 2026/1/27

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Arcutis Biotherapeutics discussion 0 comments

Add a comment